Read about 'The Future of Antibody Discovery and Cell Line Development'
‘Antibody-derived biologics have become a major class of modern medicine, particularly in the fight against cancer and autoimmune diseases. Crucial to the successful translation of antibodies into therapies are highly efficient antibody discovery and cell line development pipelines. The challenge for biopharma is to screen large cell populations for productivity, antigen-specificity, or other parameters, and then isolate rare cells with assured clonality.’
Read more about how Sphere Fluidics’ Cyto-Mine® is shaping ‘The Future of Antibody Discovery and Cell Line Development’ in the latest issue of GEN Magazine